Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records

POP BIOTECHNOLOGIES INC

UEIZWKMU75DGJY4CAGE7FCR8NAICS541714
  • SAM active
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members
  • Small Business

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$0
Awards on record
0
Contract vehicles
0
Verified credentials
0

Compliance posture: unverified (SAM.gov baseline only)

POP BIOTECHNOLOGIES INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0

Claim this profile

About POP BIOTECHNOLOGIES INC

POP BIOTECHNOLOGIES INC is a SAM.gov-registered entity based in BUFFALO, NY 14228-2710. UEI ZWKMU75DGJY4; CAGE 7FCR8; primary NAICS 541714. Compliance posture not provided. Active SAM registration.
Headquarters
BUFFALO, NY 14228-2710

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIZWKMU75DGJY4
  • CAGE7FCR8

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

No federal prime awards on record

USAspending shows no prime awards for this UEI in the last 36 months. Subcontract work does not appear here.

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Who POP BIOTECHNOLOGIES INC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
12 awards
Total awarded
$8,781,806
By phase
  • SBIR Phase I: 4
  • STTR Phase I: 4
  • SBIR Phase II: 2
  • STTR Phase II: 2
By agency
  • Department of Health and Human Services: 12
Active projects
2 projects
Projects whose contract end date is today or later.
Phase II ending within 12 months
1 project
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2025: 1
  • 2024: 3
  • 2023: 2
  • 2022: 1
  • 2021: 1
  • 2020: 2
  • 2019: 1
  • 2018: 1

Awards (most recent first)

  • Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes

    STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $833,334

    Sep 20, 2025 – May 31, 2028

    • Active

    Solicitation PAS22-197 (2022) · Topic NIA · Research partner: RESEARCH FOUNDATION FOR MENTAL HYGIENE

  • Liposome-displayed peptide vaccine against disseminated candidiasis by clinically-relevant Candida species

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $600,000

    Aug 1, 2024 – Jul 31, 2026

    Solicitation PA23-232 (2023) · Topic R41 · Research partner: LOUISIANA STATE UNIV A&M COL BATON ROUGE

  • Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,899,426

    Jun 1, 2024 – May 31, 2027

    • Active
    • Ends May 2027

    Solicitation PA22-176 (2022) · Topic NIAID

  • Clinical Translation of Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $249,873

    Apr 1, 2024 – Mar 31, 2025

    Solicitation PAR20-128 (2020) · Topic 102

  • Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $496,569

    Sep 15, 2023 – Jul 31, 2025

    Solicitation PAS19-317 (2019) · Topic NIA · Research partner: INSTITUTE FOR BASIC RES IN DEV DISABIL

  • POP TECHNOLOGIES, INC., ""MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE"".

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $599,806

    Solicitation PHS-2023-1 (2023) · Topic 117

  • Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,000,000

    Sep 8, 2022 – Jul 31, 2024

    Solicitation PA20-265 (2020) · Topic NCI · Research partner: ROSWELL PARK CANCER INSTITUTE CORP

  • Developing a Thermostable SARS-CoV-2 RBD-particle Vaccine

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $599,982

    Jul 9, 2021 – Jun 30, 2023

    Solicitation PA20-260 (2020) · Topic NIAID

  • Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $399,917

    Apr 6, 2020 – Mar 31, 2021

    Solicitation PA19-270 (2019) · Topic 102 · Research partner: ROSWELL PARK CANCER INSTITUTE CORP

  • An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $223,797

    Feb 10, 2020 – Jan 31, 2021

    Solicitation PA18-575 (2018) · Topic NIAID · Research partner: STATE UNIVERSITY NEW YORK STONY BROOK

  • A Liposomal Platform for Spontageous, Particleized Presentation of HIV Trimer Immunogens

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $599,897

    Solicitation year 2018 · Topic NIAID

  • Scalable Formulation and Production of Photosensitive Nanoparticles for Cancer Therapy

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $279,205

    Sep 6, 2018 – Aug 31, 2019

    Solicitation PA17-302 (2017) · Topic 102

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.

NAICS, PSC & socio-economic status

Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
  • 325414Biological Product (except Diagnostic) ManufacturingSmall business under this code’s size standard

SAM.gov reports this entity as small under 2 of 2 NAICS codes. Size is determined per code (SBA size standards).

Product & service codes (PSC)

  • AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
  • AJ12GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH
  • AJ13GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; EXPERIMENTAL DEVELOPMENT
  • AJ14GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; R&D ADMINISTRATIVE EXPENSES
  • AJ15GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; R&D FACILITIES & MAJ EQUIP
  • AN22HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH
  • AN24HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; R&D ADMINISTRATIVE EXPENSES
  • AN25HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; EXPENSES FOR R&D FACILITIES AND MAJOR EQUIPMENT

PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.
  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with POP BIOTECHNOLOGIES INC?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.